Protocol Ledger

NCT04208347 · Phase II/III · ACTIVE NOT RECRUITING

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Interventional Phase II/III clinical trial protocol NCT04208347 sponsored by Ruijin Hospital in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-12-18 Enrollment: 580 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04208347
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)580 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04208347
Protocol FieldVerified Registry Value
NCT IdentifierNCT04208347
Consolidated Lead SponsorRuijin Hospital
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment580 participants (ESTIMATED)
Registered Start Date2019-12-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI